文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

血小板源性生长因子受体α在胶质瘤中的表达与局部炎症及生存相关。

Podoplanin expression is associated with local inflammation and survival in glioma.

作者信息

Mir Seyed Nazari Pegah, Mair Maximilian J, Riedl Julia, Schöllkopf Benedikt, Moik Florian, Ricken Gerda, Widhalm Georg, Dieckmann Karin, Ay Cihan, Pabinger Ingrid, Preusser Matthias, Berghoff Anna Sophie

机构信息

Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

出版信息

Sci Rep. 2025 Aug 29;15(1):31833. doi: 10.1038/s41598-025-12709-w.

DOI:10.1038/s41598-025-12709-w
PMID:40883334
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12397430/
Abstract

Glioma subtypes differ in prognosis and treatment strategies. We aimed to determine the correlation of podoplanin (PDPN) expression in glioma subtypes with survival as well as systemic and local inflammation. In a prospective cohort study including 192 patients with glioma, tumor-infiltrating lymphocytes (TILs), programmed cell death ligand 1 (PD-L1) expression and podoplanin (PDPN) expression were analyzed by immunohistochemistry. PDPN and PD-L1 expression were more frequently observed in IDH1 wildtype (wt) compared to IDH1 mutant (mut) glioma (p = 0.015). In IDHwt glioma, overall survival was significantly longer in glioma patients without PDPN expression compared to those with PDPN expression (median 26.3 vs. 12.5 months, log-rank test, p < 0.001). Levels of tumor-infiltrating CD8 + and CD68 + cells were highest in IDH1wt glioma with both PDPN and PD-L1 expression (p < 0.001). IDH1wt, PDPN and non-PD-L1 expressing glioma presented with the highest neutrophil-to-lymphocyte (NLR) ratio in the blood compared to other subtypes (p = 0.023). Gliomas differ in the composition of the inflammatory microenvironment according to the presence of IDH1 mutation. Podoplanin, a marker of innate inflammation, is associated with survival prognosis and systemic inflammation in patients with IDH1wt glioma.

摘要

胶质瘤亚型在预后和治疗策略上存在差异。我们旨在确定胶质瘤亚型中足突蛋白（PDPN）表达与生存率以及全身和局部炎症之间的相关性。在一项纳入192例胶质瘤患者的前瞻性队列研究中，通过免疫组织化学分析肿瘤浸润淋巴细胞（TILs）、程序性细胞死亡配体1（PD-L1）表达和足突蛋白（PDPN）表达。与异柠檬酸脱氢酶1（IDH1）突变（mut）的胶质瘤相比，IDH1野生型（wt）胶质瘤中更频繁观察到PDPN和PD-L1表达（p = 0.015）。在IDHwt胶质瘤中，与有PDPN表达的患者相比，无PDPN表达的胶质瘤患者总生存期显著更长（中位生存期26.3个月对12.5个月，对数秩检验，p < 0.001）。在同时表达PDPN和PD-L1的IDH1wt胶质瘤中，肿瘤浸润的CD8 +和CD68 +细胞水平最高（p < 0.001）。与其他亚型相比，IDH1wt、表达PDPN且不表达PD-L1的胶质瘤患者血液中的中性粒细胞与淋巴细胞（NLR）比值最高（p = 0.023）。根据IDH1突变的存在情况，胶质瘤的炎症微环境组成存在差异。足突蛋白作为一种先天性炎症标志物，与IDH1wt胶质瘤患者的生存预后和全身炎症相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe82/12397430/4e37b0f8952c/41598_2025_12709_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe82/12397430/a517de2afe3a/41598_2025_12709_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe82/12397430/10703e0ad792/41598_2025_12709_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe82/12397430/4e37b0f8952c/41598_2025_12709_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe82/12397430/a517de2afe3a/41598_2025_12709_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe82/12397430/10703e0ad792/41598_2025_12709_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe82/12397430/4e37b0f8952c/41598_2025_12709_Fig3_HTML.jpg

相似文献

[1]
Podoplanin expression is associated with local inflammation and survival in glioma.

Sci Rep. 2025-8-29

[2]
Predicting podoplanin expression and prognostic significance in high-grade glioma based on TCGA TCIA radiomics.

PLoS One. 2025-6-24

[3]
Correlation of immune phenotype with IDH mutation in diffuse glioma.

Neuro Oncol. 2017-10-19

[4]
High ELK3 expression is associated with the wild type IDH1 in glioma and enhances infiltration of M2 macrophages.

Int Immunopharmacol. 2025-8-28

[5]
The advanced development of Cx43 and GAP-43 mediated intercellular networking in IDH1 wildtype diffuse and anaplastic gliomas with lower mitotic rate.

J Cancer Res Clin Oncol. 2021-10

[6]
High matrix metalloproteinase-2 expression predicts poor prognosis of colon adenocarcinoma and is associated with PD-L1 expression and lymphocyte infiltration.

PeerJ. 2025-6-30

[7]
Proteomic profiling identifies a stromal TGF-β1/podoplanin axis as a driver of colorectal cancer progression.

J Exp Clin Cancer Res. 2025-8-22

[8]
Correlation between Isocitrate Dehydrogenase Mutation and Immunohistochemical Expression of DNA Mismatch Repair Proteins in the Prognosis of Gliomas.

Asian Pac J Cancer Prev. 2025-4-1

[9]
Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.

J Cancer Res Clin Oncol. 2019-3-14

[10]
Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors.

Neuro Oncol. 2025-1-12

本文引用的文献

[1]
Platelets and diseases: signal transduction and advances in targeted therapy.

Signal Transduct Target Ther. 2025-5-16

[2]
The role of platelets in cancer: from their influence on tumor progression to their potential use in liquid biopsy.

Biomark Res. 2025-2-11

[3]
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.

Nat Med. 2024-5

[4]
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.

N Engl J Med. 2024-4-11

[5]
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.

Nat Med. 2024-4

[6]
Effects of the interactions between platelets with other cells in tumor growth and progression.

Front Immunol. 2023

[7]
Overexpression of Podoplanin Predicts Poor Prognosis in Patients With Glioma.

Appl Immunohistochem Mol Morphol. 2023

[8]
PDPN marks a subset of aggressive and radiation-resistant glioblastoma cells.

Front Oncol. 2022-8-10

[9]
Platelets at the Crossroads of Pro-Inflammatory and Resolution Pathways during Inflammation.

Cells. 2022-6-17

[10]
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.

Neuro Oncol. 2022-11-2

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索